

**SAFETY Meeting Minutes**  
UAMS IBC

**MEETING TIME RECORDS**

**Meeting start time:** 10/3/2025 12:01 PM

**Meeting end time:** 10/3/2025 01:11 PM

**Meeting type:** Virtual

| <b>Name of Regular/Alternate Member</b> | <b>Status (Member or Alternate)</b> | <b>Present by Teleconference?</b> |
|-----------------------------------------|-------------------------------------|-----------------------------------|
| Ha-Neui Kim                             | Member                              | Yes                               |
| Matthew Jorgenson                       | Member                              | Yes                               |
| Robert Hunter                           | Member                              | No                                |
| Kimberly Murphy                         | Member                              | Yes                               |
| Lindsey Clark                           | Member                              | No                                |
| James Douglas                           | Member                              | Yes                               |
| Amanda Holloway                         | Ex Officio                          | No                                |
| James Bishop                            | Member                              | No                                |
| Youssef Aachoui                         | Member                              | Yes                               |
| Jia Liu                                 | Member                              | Yes                               |
| Yuet-Kin Leung                          | Member                              | Yes                               |
| Melaney Gee                             | Member                              | Yes                               |
| Mark Manzano                            | Member                              | Yes                               |
| Christine Simecka Morgan                | Member                              | No                                |
| Antino Allen                            | Member                              | Yes                               |
| KyoungHyun Kim                          | Member                              | Yes                               |
| James Townsend                          | Ex Officio                          | Yes                               |
| Shengyu Mu                              | Member                              | Yes                               |
| Kikumi Ono-Moore                        | Ex Officio                          | Yes                               |
| Zhiqiang Qin                            | Member                              | Yes                               |

**QUORUM INFORMATION**

**Number of SAFETY members on the roster:** 17

**Number required for quorum:** 9

**Quorum:** Present

All members present via teleconference received all pertinent material before the meeting and were able to actively and equally participate in all discussions.

| ATTENDANCE STATUS AND VOTING KEY |                                                                                                                                                                                                                                                                                                                                |
|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ABSTAIN:                         | Present for the vote but not voting “For” or “Against.”                                                                                                                                                                                                                                                                        |
| ABSENT:                          | Absent for discussion and voting for reasons other than a conflict of interest.                                                                                                                                                                                                                                                |
| RECUSED:                         | Absent from the meeting during discussion and voting because of a conflict of interest.                                                                                                                                                                                                                                        |
| SUBSTITUTION:                    | When regular members and their alternate(s) are listed in the ATTENDANCE table above and an alternate member serves as a substitute for the regular member this identifies the name of the alternate to indicate which individual is serving as the voting member for this vote. May be deleted if there are no substitutions. |

| GUEST NAMES |
|-------------|
| N/A         |
|             |
|             |

**Previous Meeting minutes approved:** Yes

## REVIEW OF SUBMISSIONS

The review and discussion of the protocols listed below included the following elements: the agents involved and their characteristics; types of manipulations planned; the source(s) and nature of the nucleic acid sequences; the host organism(s) and vector(s) to be utilized; whether expression of a foreign gene is intended and, if so, the specific protein(s) to be produced; the containment conditions to be applied, including biosafety level and any special provisions; and the relevant sections of the NIH Guidelines.

All IBC members present were reminded to identify any conflicts of interest as each registration was reviewed.

For each protocol reviewed, it was confirmed that the Principal Investigator (PI) and laboratory personnel have received appropriate training in the safe conduct of research.

**Amendment****1. Review of SAMEND202500000116**

|                            |                                                                                                                                                                                                                                                                |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title:                     | Amendment for SPROTO202500000036                                                                                                                                                                                                                               |
| Investigator:              | <a href="#">Abdelrahman Fouda</a>                                                                                                                                                                                                                              |
| Submission ID:             | SAMEND202500000116                                                                                                                                                                                                                                             |
| Description:               | <ul style="list-style-type: none"> <li>- Adding in vivo studies for generating the inducible endothelial HDAC3 knockout mice using AAV constructs.</li> <li>- Adding in vitro studies for overexpressing hexokinase 2 using Adenovirus transfection</li> </ul> |
| Agent Containment:         | Biological Containment Levels: <ul style="list-style-type: none"> <li>• Adenoassociated virus AAV: BSL-2</li> <li>• Adenovirus: BSL-2</li> </ul>                                                                                                               |
| Applicable NIH Guidelines: | <ul style="list-style-type: none"> <li>• Section III-D-1-a</li> <li>• Section III-F-1</li> </ul>                                                                                                                                                               |

a. **Determination:** Modifications Required

b. **Required modifications:**

Committee Determination: Modifications Required.

Please review and respond to all comments throughout submission.

c. **Votes:**

|                   |    |
|-------------------|----|
| <b>For:</b>       | 13 |
| <b>Against:</b>   | 0  |
| <b>Recused:</b>   | 0  |
| <b>Absent:</b>    | 4  |
| <b>Abstained:</b> | 0  |

**Initial Protocol****2. Review of SPROTO202500000063**

|                |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title:         | Biomarkers involved in BPD-PH                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Investigator:  | <a href="#">Roopa Siddaiah</a>                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Submission ID: | SPROTO202500000063                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Description:   | <p>o In our research, we will investigate the target pathways involved in bronchopulmonary dysplasia associated with pulmonary hypertension (BPD-PH) – a condition associated with abnormal development and growth of lung blood vessels and elevated pulmonary artery pressure - in preterm infants. We will use this study to analyze mechanistic pathways of micro-RNAs (miRNA) and their target gene expression that play a role in BPD-PH.</p> |

|                            |                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | <ul style="list-style-type: none"> <li>o The protocol will encompass evaluating the role of miRNA in the pathobiology of BPD-PH through culture of key cell lines from both patient derived samples and from commercially available cell lines in different states of oxidative stress.</li> <li>o All transfection work will be performed in full PPE within a Biosafety Cabinet (BSC).</li> </ul> |
| Agent Containment:         | Biological Containment Levels: <ul style="list-style-type: none"> <li>• Nasal Secretions: BSL-2</li> <li>• Human Umbilical Vein Endothelial Cell Line (HUVEC): BSL-2</li> <li>• Fibroblasts: BSL-2</li> <li>• Human Tracheal Aspirate: BSL-2</li> <li>• Human Vascular Smooth Muscle Cells: BSL-2</li> <li>• iPSC-derived Human Alveolar Type 2-like Cells: BSL-2</li> </ul>                        |
| Applicable NIH Guidelines: | <ul style="list-style-type: none"> <li>• Section III-D-1-a</li> <li>• Section III-D</li> </ul>                                                                                                                                                                                                                                                                                                      |

- a. **Determination:** Modifications Required
- b. **Required modifications:**  
 Committee Determination: Modifications Required.  
 Please review and respond to all comments throughout submission.

- c. **Votes:**
- |                   |    |
|-------------------|----|
| <b>For:</b>       | 13 |
| <b>Against:</b>   | 0  |
| <b>Recused:</b>   | 0  |
| <b>Absent:</b>    | 4  |
| <b>Abstained:</b> | 0  |

## Initial Protocol

### 3. Review of SPROTO202500000067

|                |                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title:         | Investigating new oncogenic mechanisms                                                                                                                                                                                                                                                                                                                                                                             |
| Investigator:  | <a href="#">Samantha Kendrick</a>                                                                                                                                                                                                                                                                                                                                                                                  |
| Submission ID: | SPROTO202500000067                                                                                                                                                                                                                                                                                                                                                                                                 |
| Description:   | This protocol involves studies aimed at uncovering the oncogenic mechanisms underlying aggressive diffuse large B cell lymphoma (DLBCL) to develop new approaches to sensitize these tumors to therapy. Studies utilize human cell lines derived from DLBCL patients, human DLBCL formalin-fixed paraffin embedded tissues, the DT40 chicken B cell line, EBV immortalized germinal center B-cell lines, and mouse |

|                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | models as well as ex vivo (test tube only) under BL2 conditions. Reporter genes (GFP and LUC) and proteins (e.g. AID, REV1) will be expressed in cells for measuring the effect on transcription and cytidine deaminase activities, along with use of synthetic DNA for ex vivo work covered by NIH guidelines Sections III-D-2-a and III-F-2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Agent Containment:         | <p>Biological Containment Levels:</p> <ul style="list-style-type: none"> <li>• Primary Human Tissue: BSL-2</li> <li>• Human Tumor Tissue: BSL-2</li> <li>• E. coli: BSL-1</li> <li>• GM22671 Human Cell Line: BSL-2</li> <li>• HBL-1 Human Cell Line: BSL-2</li> <li>• Hs578Bst (normal mammary, ER-neg) Human Cell Line: BSL-2</li> <li>• MCF7 Human Cell Line: BSL-2</li> <li>• HT Human B Cell Lymphoma Cell Line: BSL-2</li> <li>• GM03714 Human Cell Line: BSL-2</li> <li>• SU-DHL-4 Human Cell Line (SUDHL4): BSL-2</li> <li>• GM03798 Human Cell Line: BSL-2</li> <li>• SU-DHL-5 Human Cell Line (SUDHL5): BSL-2</li> <li>• GM12593 Human Cell Line: BSL-2</li> <li>• SU-DHL-10 Human Cell Line (SUDHL10): BSL-2</li> <li>• MDA-MB-231 (Human TNBC cell line): BSL-2</li> <li>• DB Human Cell Line: BSL-2</li> <li>• RI-1 Human Cell Line (RIVA): BSL-2</li> <li>• GM16113 Human Cell Line: BSL-2</li> <li>• U2932 Human Cell Line: BSL-2</li> <li>• GM23349 Human Cell Line: BSL-2</li> <li>• Hs578T (breast carcinoma, ER-neg) Human Cell Line: BSL-2</li> <li>• VAL Human Cell Line: BSL-2</li> <li>• SU-DHL-6 Human Cell Line (SUDHL6): BSL-2</li> <li>• GM24008 Human Cell Line: BSL-2</li> <li>• Expi293F: BSL-2</li> <li>• HEK293T Human Cell Line: BSL-2</li> </ul> |
| Applicable NIH Guidelines: | <ul style="list-style-type: none"> <li>• Section III-F-2</li> <li>• Section III-F</li> <li>• Section III-D-2-a</li> <li>• Section III-D</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

a. **Determination:** Modifications Required

b. **Required modifications:**

Committee Determination: Modifications Required.

Please review and respond to all comments throughout submission.

c. **Votes:**

**For:** 13  
**Against:** 0  
**Recused:** 0  
**Absent:** 4  
**Abstained:** 0

## De Novo Review

### 4. Review of SPROTO202500000059

|                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title:         | Musculoskeletal Effects of Hormones                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Investigator:  | <a href="#">Teresita Bellido</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Submission ID: | SPROTO202500000059                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Description:   | <p>Our research focuses on the cellular and molecular mechanisms by which osteocytes, the most abundant cells in bone, regulate skeletal remodeling in response to mechanical, hormonal, and pathological signals. We aim to elucidate how osteocyte signaling contributes to bone loss in diabetes and multiple myeloma (MM), and to develop genetic and pharmacological strategies to restore bone health.</p> <p>In our diabetes studies, we use a murine model where we induce diabetes through high-fat diet and streptozotocin (STZ) to examine the progression of diabetic bone disease and test therapeutic interventions. We investigate the role of oxidative stress (via Cyba knockout) and osteocyte-specific PTH receptor signaling (PTH1R flox/flox; DMP1-8kb-Cre) in diabetic bone fragility. Pharmacological treatments include Parathyroid hormone (PTH), Abaloparatide (ABL), a SIK inhibitor (SK-124), and an LXR inhibitor (GW3965). Bone phenotype is assessed through longitudinal imaging (bone mineral density, in-vivo <math>\mu</math>CT), serum biomarkers, mechanical testing, histology, gene expression, single-cell RNA sequencing and lipidomics. Additionally, in-vitro and ex-vivo cultures of osteocytes and murine bones are used to evaluate treatment effects under normal and high glucose conditions. Human bone samples from diabetic patients will be analyzed to validate key transcriptional changes observed in murine models. (IRB pending).</p> <p>In our multiple myeloma (MM) studies, we explore how osteocyte-derived VEGFA contributes to angiogenesis in MM tumor microenvironment. Using mice with osteocyte-specific deletion of Vegfa (Vegfa flox/flox; DMP1-8kb-Cre) we assess MM-induced bone disease following intratibial or systemic injection of murine MM cells (VK12653). Tumor burden and</p> |

|                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | bone loss are evaluated via serum IgG $\lambda$ 2, $\mu$ CT, and histological analyses. Further we utilize in-vitro co-cultures of MM cells and osteocyte-like cell lines (MLO-A5, MLO-Y4, OCY454) treated with GSI-XII (Notch inhibitor) or Infigratinib (FGFR inhibitor) to identify signaling mechanisms driving osteocyte–MM interactions using gene expression assays (quantitative PCR) on the cells. We also perform ex-vivo studies, we inoculate / co-culture murine long bones, vertebra or calvaria with MM cells with and without the inhibiting agents followed by gene expression. |
| Agent Containment:         | <p>Biological Containment Levels:</p> <ul style="list-style-type: none"> <li>• MLO-A5: BSL-1</li> <li>• Vk12653 Murine Bortezomib-Resistant Myeloma Cell Line: BSL-1</li> <li>• Animal Blood: BSL-2</li> <li>• 5TGM1: BSL-1</li> <li>• Animal Tissue: BSL-2</li> <li>• C2C12 Murine Myoblast Cell Line: BSL-1</li> <li>• MLO-Y4: BSL-1</li> <li>• Primary Human Tissue: BSL-2</li> <li>• Ocy454: BSL-1</li> <li>• OPM2: BSL-2</li> <li>• Animal Cells: BSL-2</li> <li>• JJN3: BSL-2</li> <li>• Human Umbilical Vein Endothelial Cell Line (HUVEC): BSL-2</li> </ul>                              |
| Applicable NIH Guidelines: | <ul style="list-style-type: none"> <li>• Section III-E-3</li> <li>• Section III-C</li> <li>• Section III-E-3-a</li> <li>• Section III-F-8-C-I</li> <li>• Section III-D-4</li> <li>• Section III-F</li> <li>• Section III-E</li> <li>• Section III-F-8-C-VII</li> <li>• Section III-D</li> <li>• Section III-F-8-C-VIII</li> </ul>                                                                                                                                                                                                                                                                |

- a. **Determination:** Modifications Required
- b. **Required modifications:**  
 Committee Determination: Modifications Required.  
 Please review and respond to all comments throughout submission.
- c. **Votes:**
- |                 |    |
|-----------------|----|
| <b>For:</b>     | 13 |
| <b>Against:</b> | 0  |
| <b>Recused:</b> | 0  |

**Absent:** 4  
**Abstained:** 0

## De Novo Review

### 5. Review of SPROTO202500000069

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title:             | Mechanisms of reovirus pathogenesis (BP102)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Investigator:      | <a href="#">Karl Boehme</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Submission ID:     | SPROTO202500000069                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Description:       | <p>This protocol uses wild-type and mutant mammalian orthoreoviruses, which are non-enveloped, double-stranded RNA viruses with generally low pathogenicity in humans, to study virus-host interactions and mechanisms of viral replication, gene expression, and antiviral responses. To identify host factors, CRISPR and siRNA-based gene modification are carried out in mammalian cells. Genetically modified mice and viral mutants are used to evaluate their roles in in vivo pathogenesis under ABSL-2 containment. Additionally, Sindbis virus (an enveloped, positive-sense RNA virus used as an expression vector), vesicular stomatitis virus (VSV; an enveloped, negative-sense RNA virus used as a control for replication and immune induction), murine gammaherpesvirus-68 (MHV68; used only in vitro), and replication-deficient Moloney-murine leukemia virus (MMLV) are used for various purposes. Viral vectors and expression systems based on plasmids, retroviruses, or Sindbis virus—including recombinant His-tagged SARS-CoV-2 Spike protein constructs—are employed for both transient and stable gene expression. A replication-deficient MMLV pseudotyped with SARS-CoV-2 Spike protein and containing a GFP reporter is used in serum neutralization assays. All viral vectors and human serum samples (which are heat-inactivated at 56°C for 1 hour prior to testing) are handled using BSL-2 precautions, including BSC containment, sample fixation, and strict biohazard waste management according to institutional biosafety guidelines.</p> |
| Agent Containment: | <p>Biological Containment Levels:</p> <ul style="list-style-type: none"> <li>• Animal Tissue: BSL-2</li> <li>• Human Serum: BSL-2</li> <li>• Sindbis virus: BSL-2</li> <li>• MHV68: BSL-2</li> <li>• Rhinovirus: BSL-2</li> <li>• Reovirus: BSL-2</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |



|                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | <ul style="list-style-type: none"> <li>• Retrovirus: BSL-2</li> <li>• E. coli: BSL-2</li> <li>• NIH3T12: BSL-1</li> <li>• A-253: BSL-2</li> <li>• H1437: BSL-2</li> <li>• THP-1: BSL-2</li> <li>• MEF (Mouse Embryo Fibroblasts): BSL-1</li> <li>• COS-7 (African green monkey kidney fibroblast-like cell line): BSL-2</li> <li>• A549: BSL-2</li> <li>• U937: BSL-2</li> <li>• H1563: BSL-2</li> <li>• Detroit 562: BSL-2</li> <li>• BHK-21: BSL-1</li> <li>• Vero: BSL-2</li> <li>• WisL: BSL-2</li> <li>• H1573: BSL-2</li> <li>• MDCK-I : BSL-1</li> <li>• H1975: BSL-2</li> <li>• H1299 (NSCLC cell line): BSL-2</li> <li>• BHK-T7: BSL-2</li> <li>• 293: BSL-2</li> <li>• H2126: BSL-2</li> <li>• MDCK-II: BSL-1</li> <li>• SVEC4-10: BSL-1</li> <li>• SCC-9: BSL-2</li> <li>• 293T: BSL-2</li> <li>• L929: BSL-1</li> <li>• SCC-15: BSL-2</li> <li>• FaDu: BSL-2</li> <li>• HeLa cells: BSL-2</li> <li>• Mouse erythroleukemia (MEL): BSL-1</li> <li>• TX111: BSL-2</li> <li>• NIH3T3: BSL-1</li> <li>• SCC-25: BSL-2</li> <li>• RAW 264.7 Macrophage Cell Line: BSL-1</li> <li>• H661: BSL-2</li> <li>• Jurkat T Cells: BSL-2</li> </ul> |
| Applicable NIH Guidelines: | <ul style="list-style-type: none"> <li>• Section III-D-1</li> <li>• Section III-D-2</li> <li>• Section III-D-3</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

a. **Determination:** Modifications Required

b. **Required modifications:**

Committee Determination: Modifications Required.

Please review and respond to all comments throughout submission.

**c. Votes:**

|                   |    |
|-------------------|----|
| <b>For:</b>       | 13 |
| <b>Against:</b>   | 0  |
| <b>Recused:</b>   | 0  |
| <b>Absent:</b>    | 4  |
| <b>Abstained:</b> | 0  |

**REVIEW OF OTHER AGENDA ITEMS**

- Administrative approvals were acknowledged and approved.
- No Safety Incidents to report
- No Inspection Findings to report
- The 'IBC Roles and Responsibilities' document was discussed again, and reviewers were reminded that they are now responsible for resolving their own comments in Muse.
  - The Chair indicated that she has suggested edits to the document and would communicate these to the Safety Coordinating Committee (SCC). No concerns were mentioned by members.